FY2024 · ended Dec 31, 2024 · Revenue $780,000, -33.7% YoY · Filed Mar 30, 2026
Valion Bio, Inc. (VBIO) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$7.0 million. As of Jun 30, 2026 it held $2.1 million in cash and investments and $10.0 million in total debt.
Revenue (TTM)
$482,000
-49.6% vs year-ago TTM
Net income (TTM)
$-7.51M
-16.9% vs year-ago TTM
Operating cash flow (TTM)
$-14.57M
-165.6% vs year-ago TTM
Free cash flow (TTM)
$-14.67M
-167.2% vs year-ago TTM
EPS
$-19.68
+88.9% vs prior year
Dividend per share
None
Shares outstanding
2.88M
+364.1% vs prior year
Net cash
$-7.91M
as of Jun 30, 2026
Operating margin
-1290.7%
FY 2025
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- VBIO (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Antonio, TX
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1787740
- Former names
- Tivic Health Systems, Inc. (until Apr 23, 2026)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
|---|---|---|---|---|
| Revenue | — | $780,000 | $1.2M | $1.8M |
| Operating income | -$7.9M | -$4.5M | -$8.2M | -$10.1M |
| Net income | -$8.9M | -$5.7M | -$8.2M | -$10.1M |
| Diluted EPS | — | -$19.68 | -$176.80 | -$104.32 |
| Operating cash flow | -$7.0M | -$5.7M | -$8.5M | -$8.9M |
| Free cash flow | -$7.0M | — | -$8.6M | -$8.9M |
| Total assets | $31.6M | $2.8M | $5.2M | $5.9M |
| Total liabilities | $7.4M | $272,000 | $1.6M | $2.2M |
| Stockholders' equity | $16.8M | $2.5M | $3.6M | $3.6M |
| Cash and investments | $12.6M | $2.0M | $3.4M | $3.5M |
| Total debt | — | — | $369,000 | $530,000 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Officer or director change, Other events
|
Nov 2, 2026 | Oct 27, 2026 |
| 8-K |
Current report
Other events
|
Oct 29, 2026 | Oct 28, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale
|
Oct 27, 2026 | Oct 26, 2026 |
| 8-K |
Current report
Other events
|
Oct 26, 2026 | Oct 26, 2026 |
| 8-K |
Current report
Other events
|
Oct 22, 2026 | Oct 21, 2026 |
| 8-K |
Current report
Other events
|
Oct 15, 2026 | Oct 15, 2026 |
All 402 Valion Bio, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.